Last reviewed · How we verify
amoxicillin 1gr
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking peptidoglycan cross-linking.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking peptidoglycan cross-linking. Used for Bacterial infections caused by susceptible organisms (respiratory tract infections, otitis media, sinusitis, urinary tract infections, skin and soft tissue infections, streptococcal pharyngitis), Helicobacter pylori eradication (as part of combination therapy).
At a glance
| Generic name | amoxicillin 1gr |
|---|---|
| Sponsor | Rabin Medical Center |
| Drug class | Beta-lactam antibiotic (aminopenicillin) |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Amoxicillin is a beta-lactam antibiotic that penetrates bacterial cell walls and irreversibly binds to penicillin-binding proteins, preventing the cross-linking of peptidoglycan strands. This disrupts cell wall integrity, leading to bacterial cell lysis and death. It is bactericidal and effective against a broad spectrum of gram-positive and some gram-negative bacteria.
Approved indications
- Bacterial infections caused by susceptible organisms (respiratory tract infections, otitis media, sinusitis, urinary tract infections, skin and soft tissue infections, streptococcal pharyngitis)
- Helicobacter pylori eradication (as part of combination therapy)
Common side effects
- Diarrhea
- Nausea
- Rash
- Allergic reaction / anaphylaxis
- Vomiting
- Abdominal pain
Key clinical trials
- Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Tegoprazan vs Esomeprazole (PHASE4)
- Concomitant Versus Hybrid Regimen for H. Pylori Eradication (PHASE4)
- Genotypic Resistance-guided Versus Empirical Therapy for H. Pylori Eradication. (PHASE4)
- 10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection (PHASE4)
- High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- amoxicillin 1gr CI brief — competitive landscape report
- amoxicillin 1gr updates RSS · CI watch RSS
- Rabin Medical Center portfolio CI